Related Experiment Video
Updated: Apr 28, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Natural Products in Endometrial Cancer: Molecular Mechanisms, Preclinical Evidence, and Clinical Perspectives
Hsien-Chang Wu1,2, Chung-Che Tsai3,4, Chan-Yen Kuo5
1School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 970374, Taiwan.
Abstract:
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with increasing incidence linked to obesity and metabolic dysfunction. While early-stage EC is often curable, advanced and recurrent disease remains difficult to treat due to resistance and limited therapeutic options. Natural products derived from traditional Chinese medicine have attracted attention as complementary strategies in EC management. These compounds exhibit multi-target effects, including modulation of estrogen signaling, inhibition of proliferation, induction of apoptosis, and regulation of immune and inflammatory pathways. This review summarizes current evidence on natural products in EC, integrating preclinical findings, emerging clinical data, and mechanistic insights from molecular and systems biology approaches. Key challenges, including variability, bioavailability, and insufficient clinical validation, are discussed. Future directions emphasize the integration of natural products into precision oncology frameworks.
Insights
Natural products show promise for treating endometrial cancer (EC), especially advanced or recurrent forms. Further research is needed to overcome challenges like bioavailability and clinical validation for integrating these therapies into precision oncology.
Area of Science:
- Gynecologic Oncology
- Pharmacology
- Integrative Medicine
Background:
- Endometrial cancer (EC) is a prevalent gynecologic malignancy, with rising incidence linked to obesity and metabolic issues.
- Advanced or recurrent EC presents significant treatment challenges due to resistance and limited options.
- Natural products from traditional Chinese medicine offer potential complementary strategies for EC management.
Purpose of the Study:
- To review current evidence on natural products in endometrial cancer (EC) treatment.
- To integrate preclinical findings, clinical data, and mechanistic insights.
- To identify challenges and future directions for natural product integration in EC therapy.
Main Methods:
- Literature review of preclinical studies, clinical data, and molecular/systems biology research.
- Analysis of natural product mechanisms, including estrogen signaling, proliferation, apoptosis, and immune pathways.
- Discussion of challenges such as compound variability, bioavailability, and clinical validation.
Main Results:
- Natural products demonstrate multi-target effects beneficial for EC, such as anti-proliferative and pro-apoptotic activities.
- Evidence spans preclinical findings to emerging clinical data, supported by mechanistic insights.
- Key challenges hindering clinical application include variability, bioavailability, and insufficient validation.
Conclusions:
- Natural products hold therapeutic potential for endometrial cancer, particularly in advanced or recurrent cases.
- Overcoming challenges in bioavailability, standardization, and clinical validation is crucial.
- Integrating natural products into precision oncology frameworks represents a promising future direction for EC treatment.
